Ketoconazole vs LGD-4033
FDA Approved vs Moderate Research
monitor Mechanism-based · 51% Both Ketoconazole and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects.
Molecular Data
Ketoconazole LGD-4033
Weight 531.43 Da 338.25 Da
Half-life Topical application stays local with minimal systemic absorption ~24-36 hours
Type Synthetic imidazole antifungal Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Ketoconazole
01 Disrupts DHT binding at the follicle level with topical application
02 Reduces Malassezia colonization and scalp inflammation associated with hair loss
03 Negligible systemic absorption when used as a shampoo
04 FDA-approved and widely available over the counter (1%) or by prescription (2%)
05 Part of the established "big 3" hair loss protocol with finasteride and minoxidil
06 Treats concurrent seborrheic dermatitis and dandruff while addressing hair loss
07 Simple to incorporate into existing shower routines
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Side Effects
Ketoconazole
Scalp dryness with regular use
Mild scalp irritation or itching at application site
Changes in hair texture (temporary dryness or coarseness)
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Known hypersensitivity to ketoconazole or any imidazole antifungal
Open wounds or severely broken skin on the scalp
Oral ketoconazole is contraindicated in liver disease (not applicable to shampoo use)
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Ketoconazole LGD-4033
Status FDA Approved Moderate Research
References 4 studies 5 studies
Latest — 2018
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.